Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The study examined whether gut microbial composition differs between colorectal cancer (CRC) patients who developed liver metastasis (LM) and those who did not (NLM). Researchers used high-throughput 16S rRNA sequencing to characterize microbial richness, diversity, and taxonomic composition in stool and tumor tissue samples. The goal was to identify microbial features associated with LM and poor prognosis in CRC, since liver metastasis is a major driver of mortality in advanced disease and gut microbiota has been linked to liver disease progression.
Who was studied?
The study drew on colorectal cancer patients grouped by metastasis status across three cohorts. A supplementary discovery cohort (cohort 1) analyzed primary carcinoma tissue from 8 LM and 10 NLM patients. A discovery cohort (cohort 2) used fresh feces from 18 LM and 36 NLM patients, and a validation cohort (cohort 3) used fresh feces from 13 LM and 41 NLM patients.
What were the most important findings?
Intestinal microbiota richness and diversity were higher in the LM group compared to the NLM group. Species composition differed significantly between the two groups. Across the two discovery cohorts, which used different sample types, the dominant bacterial phyla were consistent, though composition varied at lower taxonomic levels. The phylum Fusobacteria showed consistent alterations associated with liver metastasis across these analyses.
What are the greatest implications of this study?
The consistent association between Fusobacteria alterations and liver metastasis across independent discovery and validation cohorts suggests gut and tumor-associated microbiota could serve as a biomarker for metastatic risk and prognosis in colorectal cancer. This raises the possibility of using microbial profiling to help identify CRC patients at higher risk of liver metastasis. It also points toward the gut microbiota, and Fusobacteria specifically, as a potential target for future diagnostic or therapeutic strategies in advanced CRC.